OVERVIEW
Happy Saturday
Welcome to the Stockts Top 25 Newsletter this week!
The Stocks Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!
Here are the Stocks Top 25 Lists for this week:
S&P 500
Top 25 S&P 500
The S&P 500 Top 25 list -1.75%underperformed the S&P 500 index -1.63%.
There were 3 major changes to the list this week.
NASDAQ 100
The Large-Cap Nasdaq 100
The Nasdaq 100 Top 25 list -3.34% underperformed the Nasdaq 100 index -3.09%
There were 4 major changes to the list this week.
RUSSELL 2000
The Growth-Centric Russell 2000
The Russell 2000 Top 25 list -10.92% underperformed the Russell 2000 index -1.88%.
There were 6 major changes to the list this week.
Top Dawg Of The Week
The Top 25 list's Top Dawg was Terns Pharmaceuticals, which rallied 123%.
$TERN ( ▲ 1.21% ) is a clinical-stage biopharmaceutical company, developing drugs to treat non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. This week they posted positive data for TERN-701 to help people with a blood sickness called CML. After 24 weeks, more than half of patients recovered with few side affects. The company will present the findings in greater detail on its investor update call. December 8
“We are pleased that data from our CARDINAL trial have been selected for oral presentation at ASH. These data further validate the potential of TERN-701 to be a new, game-changing therapy for CML. The 24 weeks MMR achievement rate with TERN-701 is unprecedented, trending at least two times higher than the rates reported in other Phase 1 studies of CML therapies that are approved or in development,” said Amy Burroughs, chief executive officer of Terns.